Group 1 - In May, 696 out of 1025 comparable ordinary equity funds achieved positive performance, representing 68% of the total [1] - The pharmaceutical-themed funds led the performance, with 15 funds showing monthly gains exceeding 10%, including Anxin Pharmaceutical Health Stock A and C, and Hongtu Innovation Medical Care Stock [1] - Anxin Pharmaceutical Health Stock A and C had gains of 15.35% and 15.31% respectively, while Hongtu Innovation Medical Care Stock gained 15.01% [1] Group 2 - Penghua Pharmaceutical Technology Stock A and C increased by 12.44% and 12.40% respectively, managed by veteran fund manager Jin Xiaofei [2] - Other notable pharmaceutical-themed funds with significant gains include Jianxin Medical Health Industry Stock and Invesco Great Wall Medical Industry Stock [2] - Funds heavily invested in technology stocks, such as Huian Trend Power Stock A and C, underperformed with declines of 9.74% and 9.69% respectively [2] Group 3 - Funds focused on advanced manufacturing and semiconductor industries, such as GF Advanced Manufacturing Stock and Chuangjin Hexin Chip Industry Stock, experienced declines ranging from 8.56% to 7.09% [3] - The top holdings of GF Advanced Manufacturing Stock include leading companies in manufacturing and technology sectors [3] - Financial performance of the funds in the semiconductor sector showed significant changes, with some funds experiencing a net value drop of 13.98% in the first quarter [3] Group 4 - The performance rankings of ordinary equity funds in May highlighted the top gainers and losers, with Anxin Pharmaceutical Health Stock A leading the gains [4] - The data indicates a clear trend where pharmaceutical funds outperformed technology-focused funds during this period [4] - The overall market sentiment reflected a preference for healthcare-related investments amid broader market fluctuations [4]

Core Insights - The performance of actively managed equity funds in the first five months of the year shows significant disparity, with an average return of 2.62% across 4541 funds, ranging from a high of 69.30% to a low of -30.56% [2][3] Performance Overview - The major indices, including the Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index, experienced declines of 0.13%, 3.59%, and 6.93% respectively [2] - Among 31 industry indices, 16 saw gains while 15 declined, indicating a nearly even split in performance [2] - The average returns for different types of funds were as follows: ordinary stock funds (3.43%), equity hybrid funds (3.21%), flexible allocation funds (1.22%), and balanced hybrid funds (-0.08%) [2] Top Performing Funds - A total of 77 actively managed equity funds achieved returns exceeding 30%, with 18 funds surpassing 50% [3] - The top performers were primarily in the North Exchange theme, with the North Exchange 50 Index rising by 35.74% [3] - Notable funds included: - CITIC Securities North Exchange Selected Two-Year Open A (69.30%) - Huaxia North Exchange Innovative Small and Medium Enterprises Selected Two-Year Open (67.38%) - Changcheng Pharmaceutical Industry Selected A (65.83%) [4][5] Sector Highlights - The pharmaceutical sector also showed strong performance, driven by the innovation drug segment, with several funds achieving high returns [4] - Key funds in this sector included: - AVIC Optimal Navigation A (58.03%) - Yongying Pharmaceutical Innovation Smart Selection A (57.44%) - Zhongyin Big Health A (56.21%) [4][5] Underperforming Funds - Conversely, 1811 actively managed equity funds reported negative returns, with 17 funds experiencing declines exceeding 20% [6] - The worst performers included: - Caitong Multi-Strategy Fuxin (-30.56%) - Caitong Craftsmanship Preferred One-Year Holding A (-30.53%) [6][9] - Despite a general market uptrend in May, these funds continued to decline, indicating specific management or strategy issues [7]